What Records Have to Be Kept for an Unlicensed Medical Cannabis Supply?

Supplying medical cannabis in the UK involves navigating complex regulatory pathways. This is partly because most medical cannabis products available today are unlicensed specials. In this context, “unlicensed” means the medicine does not hold a full marketing authorisation from the MHRA (Medicines and Healthcare products Regulatory Agency), not that it is illegal to possess or supply under strict medical oversight.

To ensure patient safety and compliance, healthcare professionals and suppliers must maintain a precise documentation audit trail for every supply. This blog https://bizzmarkblog.com/gmp-vs-gacp-which-one-applies-to-medical-cannabis-in-the-uk/ post breaks down the key record-keeping requirements for unlicensed medical cannabis supply, explaining the differences between licensed and unlicensed pathways, the role of specialist prescribing, and the importance of clear proof of clinical need.
Licensed vs Unlicensed Medical Cannabis: Understanding the Supply Pathways
The MHRA regulates medicines in the UK. A licensed medicine holds a marketing authorisation demonstrating that it has been rigorously assessed for quality, safety, and efficacy. Examples include Epidyolex® (a licensed cannabis-derived medicine for epilepsy). In contrast, most medical cannabis products currently prescribed in the UK are unlicensed specials. This means they lack a full MHRA marketing authorisation but can be prescribed legally under specific conditions.

Unlicensed specials are supplied via the named-patient special scheme, which allows individual patients to receive unlicensed medicines when licensed alternatives are unavailable or unsuitable.
Key differences at a glance: Aspect Licensed Medicine Unlicensed Special (Named-Patient) Regulatory approval MHRA marketing authorisation No marketing authorisation; supplied under named-patient basis Supply pathway Standard pharmaceutical supply chain Specials manufacturers/importers authorised by MHRA Prescribing By any suitable prescriber Usually by specialist clinicians, often via private clinics such as the Releaf cannabis clinic or NHS specialists Record keeping Standard GP and pharmacy records Enhanced documentation audit trail required Named-Patient Unlicensed Specials: The Legal and Record-Keeping Framework
When a specialist clinician prescribes unlicensed medical cannabis—often through a specialist private clinic like Releaf cannabis clinic or an NHS specialist service—the supply is set up under the named-patient special scheme. This scheme allows access to medicines not commercially available with full licences but needed to meet an individual patient’s clinical need.

The MHRA mandates that wholesalers, manufacturers, importers, and healthcare providers keep detailed records documenting every stage of this supply chain. These records serve as proof that the product was legally imported or manufactured and that the clinical need was verified.
Which records need to be kept? Prescription details: A signed prescription specifying the product, patient details, clinical indication, and prescriber information, confirming specialist-led decision-making. Patient consent and clinical need evidence: Documentation supporting why an unlicensed product is necessary, including prior treatment history and clinical rationale. Manufacturer or importer authorisation: Details confirming that the manufacturer or importer is authorised by the MHRA to supply specials. Batch and product traceability: Batch numbers, expiry dates, and supply documentation from authorised manufacturers or importers. Dispensing records: Pharmacy or hospital records showing the supply to the named patient, including administration or counselling notes where applicable. Audit trail of purchase and supply: Invoices, delivery notes, and transport logs linking the unlicensed product from manufacturer/importer through to the patient.
Maintaining this documentation is not merely bureaucratic “red tape.” Instead, it safeguards patient safety by ensuring authenticity, quality, and correct clinical use. These records also prove regulatory compliance during MHRA audits.
Specialist Prescribing and Private Clinic Access
Most unlicensed medical cannabis prescriptions in the UK originate from specialist clinicians due to the complex nature of these medicines. Private clinics like the Releaf cannabis clinic offer specialist consultations catering specifically to medical cannabis patients. These clinics help ensure:
Clinical need is clearly established. Prescriptions align with patient conditions where unlicensed cannabis products are justified. Comprehensive documentation is created to support the named-patient supply scheme.
This specialist approach supports the legitimacy of supply, which is crucial when audits or inspections by the MHRA occur.
Role of authorised manufacturers and importers
Only pharmaceutical manufacturers or importers authorised by the MHRA may supply unlicensed cannabis medicines. These companies are subject to regular inspections and must comply with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) standards.

Whether a product is manufactured in the UK or imported from abroad, suppliers must maintain records of product origin, batch details, and verification checks. These details are crucial for tracing any issues that could threaten patient safety.

Some specialist companies featured on resources like medicalcannabis.co.uk provide team-supported access to MHRA-authorised suppliers, strengthening the legitimacy and safety of the supply chain.
Practical Tips to Maintain Compliant Records for Unlicensed Medical Cannabis
Healthcare professionals and supply chain participants can take the following steps to build a robust documentation audit trail:
Use standardised forms for prescriptions and patient consent documented clearly with dates and signatures. Keep electronic and paper records that systematically link the patient, prescriber, product, and supplier information. Regularly verify manufacturer and importer authorisations via the MHRA website or direct correspondence. Retain all shipping and invoicing documents for a minimum of five years as per MHRA guideline. Use specialist regulatory compliance platforms or tools where available. Additional Resources and Learning Tools
To help clinicians and pharmacists stay informed about regulatory updates and practical guidance around unlicensed medical cannabis, the Pharma Journal offers an excellent resource called Listen—an audio option that summarizes recent pharmaceutical compliance news and in-depth explainers.

Clinicians interested in continuous updates can also subscribe to newsletters and detailed reports via site subscription forms available on leading medical cannabis platforms.
Summary: Why Proper Record-Keeping Matters
Unlicensed medical cannabis supply is legally imported medical cannabis UK rules https://smoothdecorator.com/what-is-releaf-cannabis-clinic-and-what-do-they-do-in-the-process/ permissible but tightly controlled. Maintaining a thorough documentation audit trail is essential for:
Demonstrating compliance with MHRA regulations Proving the legitimacy of supply through authorised pathways Showing clear clinical need and patient consent to support specialist prescribing Ensuring robust traceability from manufacture/import through to patient delivery
Ignoring these record-keeping duties not only risks regulatory action but ultimately endangers patient safety—a risk no healthcare professional or supplier should take lightly.

For those involved in the supply chain, from clinic to pharmacy, understanding and consistently applying these documentation requirements safeguards the integrity and future of medical cannabis access in the UK.